IMVT

Barnett Eva Renee

Known title: Chief Financial OfficerCIK: 0001883766

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 16, 2026

Immunovant (IMVT) releases Q1 2027 earnings call transcript. Immunovant held its Q1 2027 earnings call and made the full transcript available through Benzinga. Management discussed recent results and provided an outlook for the coming quarters. The discussion comes as the stock is in oversold territory, which could heighten market attention to the commentary.

this person other insiders at IMVT

Transaction History

IMVT▼ Sell$45K
IMVT▼ Sell$91K
IMVT▼ Sell$53K
IMVT▲ Buy$0
IMVT▼ Sell$59K
IMVT▼ Sell$52K
IMVT▼ Sell$3K
IMVT▼ Sell$99K
IMVT▼ Sell$106K
IMVT▼ Sell$94K
IMVT▼ Sell$153K
IMVT▼ Sell$115K
IMVT▼ Sell$5K
IMVT▼ Sell$87K
IMVT▼ Sell$6K
IMVT▼ Sell$133K
IMVT▼ Sell$120K
IMVT▼ Sell$273K
IMVT▼ Sell$83K
IMVT▼ Sell$115K
IMVT▲ Buy$0
IMVT▼ Sell$106K
IMVT▼ Sell$112K
IMVT▼ Sell$35K
IMVT▼ Sell$128K
IMVT▼ Sell$5K
IMVT▼ Sell$168K
IMVT▼ Sell$292K
IMVT▼ Sell$21
IMVT▼ Sell$68K
IMVT▼ Sell$52K
IMVT▲ Buy$0
IMVT▼ Sell$167
IMVT▼ Sell$75K
IMVT▼ Sell$118K
IMVT▲ Buy$0
IMVT▼ Sell$217K
IMVT▲ Buy$0
IMVT▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.